Drug Profile
Prabotulinumtoxin A - Daewoong Pharmaceuticals
Alternative Names: ABP 450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva; Prabotulinumtoxin A; PrabotulinumtoxinA-xvfsLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Developer AEON Biopharma; Daewoong Pharmaceutical; Evolus
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glabellar lines
- Phase III Hypertrophy; Muscle spasticity; Torticollis
- Phase II/III Blepharospasm; Facial wrinkles
- Phase II Migraine
- Preclinical Post-traumatic stress disorders
Most Recent Events
- 29 Mar 2024 AEON Biopharma plans a phase III trial for Migraine (Prevention) in 2H 2024
- 19 Mar 2024 AEON Biopharma held an end-of-phase II meeting held with the US FDA to discuss the protocol and study design for phase III trial for Migraine
- 18 Jan 2024 Preclinical trials in Post-traumatic stress disorders in USA (IM)